Cytomegalovirus and systemic inflammation at time of surgery is associated with worse outcomes in serous ovarian cancer
- 7 November 2020
- journal article
- research article
- Published by Elsevier BV in Gynecologic Oncology
- Vol. 160 (1), 193-198
- https://doi.org/10.1016/j.ygyno.2020.10.029
Abstract
No abstract availableKeywords
Funding Information
- National Cancer Institute
- American Cancer Society
- U.S. Department of Defense
This publication has 38 references indexed in Scilit:
- High Prevalence of Human Cytomegalovirus Proteins and Nucleic Acids in Primary Breast Cancer and Metastatic Sentinel Lymph NodesPLOS ONE, 2013
- Is HCMV a tumor promoter?Virus Research, 2011
- Leucine-rich alpha-2-glycoprotein-1 is upregulated in sera and tumors of ovarian cancer patientsJournal of Ovarian Research, 2010
- CRP identifies homeostatic immune oscillations in cancer patients: a potential treatment targeting tool?Journal of Translational Medicine, 2009
- Immunobiology of Human Cytomegalovirus: from Bench to BedsideClinical Microbiology Reviews, 2009
- Serum C-Reactive Protein as Independent Prognostic Variable in Patients with Ovarian CancerClinical Cancer Research, 2008
- C-Reactive Protein Concentrations and Subsequent Ovarian Cancer RiskObstetrics & Gynecology, 2007
- Seroprevalence of Cytomegalovirus Infection in the United States, 1988-1994Clinical Infectious Diseases, 2006
- Interleukin 1 receptor antagonist (IL-1Ra) is an acute-phase protein.JCI Insight, 1997
- Interleukin 4 inhibits the production of some acute‐phase proteins by human hepatocytes in primary cultureFEBS Letters, 1993